TSX symbol: SBS - Canadian Biotechnology Company confirms commercial expression levels of
Apo AI Milano variant and clarifies status of native Apo AI -
CALGARY, Aug. 22 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today updated a release issued on July 12, 2007 announcing that the Company had achieved commercial levels of apolipoprotein AI (native Apo AI) and apolipoprotein AI(Milano) (Apo AI Milano) accumulation in safflower seed lines. SemBioSys has confirmed in multiple assays that it has developed commercial levels of Apo AI Milano in safflower seed lines. Based on further evaluation of the existing data from native Apo AI safflower seed lines, the Company must clarify that, to date, it has not proven it has achieved commercial levels of native Apo AI accumulation in safflower.
While the assays demonstrate that native Apo AI accumulates in safflower, the commercial level threshold set by SemBioSys of 1% total seed protein expression has not yet been attained. Over the coming months SemBioSys will continue to analyze the additional safflower seed lines it currently has in development. The Company expects that the analysis of these seed lines will be complete by the end of the fourth quarter of 2007.
"While this is a setback to our native Apo AI program, we believe it is
temporary in nature. Our success with the Milano variant has given us
confidence that similar accumulation levels will be found among the
remaining native Apo AI plant lines we have created. We successfully
achieved the commercial threshold for Apo AI Milano early in our current
series of seed lines. We initially believed we had achieved a similar
outcome in an early seed line from the native Apo AI series. We are
currently, and will continue, analyzing new seed lines between now and the
end of 2007 as they be
|SOURCE SemBioSys Genetics Inc.|
Copyright©2007 PR Newswire.
All rights reserved